PTT induces systemic MDSC expansion capable of suppressing T cell proliferation and function.

<p>B16-F10 tumors were established on the flanks of C57BL/6J mice on day 0. Tumors were ablated by PTT on day 7. Mice were euthanized on day 12 for analysis. The control group consisted of untreated tumor-bearing mice (Ctrl: n = 4, PTT: n = 5). (<b>A</b>) Representative FACS plots and (<b>B</b>) corresponding quantitative data demonstrating CD11b⁺Ly6G/C⁺ cells within the spleens of control and PTT-treated mice. (<b>C</b>) Thymidine incorporation assay to measure T cell proliferation 72 hours following CD3/CD28 stimulation of splenocytes at various ratios of splenocytes to Gr-1^HighLy-6G⁺ cells (T cell: MDSC). (<b>D</b>) IFN-γ secretion to measure T cell function in response to CD3/CD28 stimulation at various ratios of splenocytes to Gr-1^HighLy-6G⁺ cells (T cell: MDSC). The data is representative of two or more experiments. *p<0.05, **p<0.01, ***p<0.001; ANOVA followed by Student's t-test with multiple comparison adjustment.